Immix Biopharma (IMMX) Payables (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Payables data on file, last reported at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 48.81% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 48.81% YoY), and the FY2025 full-year result was $10.0 million, up 85.05% from the prior year.
• Payables retreated to $4.7 million in Q1 2026, from $10.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $10.7 million in Q3 2025 to a low of $143074.0 in Q4 2022.
• A 5-year average of $4.4 million and a median of $3.5 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables surged 901.59% in 2023 and tumbled 48.81% in 2026, its largest moves.
• Tracing IMMX's Payables over 5 years: stood at $143074.0 in 2022, then surged by 901.59% to $1.4 million in 2023, then jumped by 276.02% to $5.4 million in 2024, then surged by 85.05% to $10.0 million in 2025, then sank by 52.56% to $4.7 million in 2026.
• Business Quant data shows IMMX's Payables at $4.7 million in Q1 2026, $10.0 million in Q4 2025, and $10.7 million in Q3 2025.